Nanofiber Scaffold-Based Tissue-Engineered Retinal Pigment Epithelium to Treat Degenerative Eye Diseases.
Clinical-grade manufacturing of a functional retinal pigment epithelium (RPE) monolayer requires reproducing, as closely as possible, the natural environment in which RPE grows. In vitro, this can be achieved by a tissue engineering approach, in which the RPE is grown on a nanofibrous biological or synthetic scaffold. Recent research has shown that nanofiber scaffolds perform better for cell growth and transplantability compared with their membrane counterparts and that the success of the scaffold in promoting cell growth/function is not heavily material dependent. With these strides, the field has advanced enough to begin to consider implementation of one, or a combination, of the tissue engineering strategies discussed herein. In this study, we review the current state of tissue engineering research for in vitro culture of RPE/scaffolds and the parameters for optimal scaffold design that have been uncovered during this research. Next, we discuss production methods and manufacturers that are capable of producing the nanofiber scaffolds in such a way that would be biologically, regulatory, clinically, and commercially viable. Then, a discussion of how the scaffolds could be characterized, both morphologically and mechanically, to develop a testing process that is viable for regulatory screening is performed. Finally, an example of a tissue-engineered RPE/scaffold construct is given to provide the reader a framework for understanding how these pieces could fit together to develop a tissue-engineered RPE/scaffold construct that could pass regulatory scrutiny and can be commercially successful.
1 Biosystems and Biomaterials Division, National Institute of Standards and Technology , Gaithersburg, Maryland.|2 Unit on Ocular and Stem Cell Translational Research, National Eye Institute, National Institutes of Health , Bethesda, Maryland.
Nathan A
NA
Hotaling
3 Section of Epithelial and Retinal Physiology and Disease, National Eye Institute, National Institutes of Health , Bethesda, Maryland.
Vladimir
V
Khristov
3 Section of Epithelial and Retinal Physiology and Disease, National Eye Institute, National Institutes of Health , Bethesda, Maryland.
Qin
Q
Wan
2 Unit on Ocular and Stem Cell Translational Research, National Eye Institute, National Institutes of Health , Bethesda, Maryland.
Ruchi
R
Sharma
2 Unit on Ocular and Stem Cell Translational Research, National Eye Institute, National Institutes of Health , Bethesda, Maryland.
Balendu Shekhar
BS
Jha
3 Section of Epithelial and Retinal Physiology and Disease, National Eye Institute, National Institutes of Health , Bethesda, Maryland.
Mostafa
M
Lotfi
3 Section of Epithelial and Retinal Physiology and Disease, National Eye Institute, National Institutes of Health , Bethesda, Maryland.
Arvydas
A
Maminishkis
1 Biosystems and Biomaterials Division, National Institute of Standards and Technology , Gaithersburg, Maryland.
Carl G
CG
Simon
2 Unit on Ocular and Stem Cell Translational Research, National Eye Institute, National Institutes of Health , Bethesda, Maryland.
Kapil
K
Bharti
D000818:Animals; D006801:Humans; D057139:Nanofibers / Q000737:chemistry*; D012162:Retinal Degeneration / Q000628:therapy*; D055213:Retinal Pigment Epithelium / Q000378:metabolism*; D023822:Tissue Engineering; D054457:Tissue Scaffolds / Q000737:chemistry*